US FDA approves Eli Lilly Alzheimer’s drug that slows progress of the disease

The U.S. Food and Drug Administration on Tuesday gave a green light to Eli Lilly's LLY.N donanemab for patients with early Alzheimer's, making it the second approved drug for slowing the progress of the brain-wasting disease.